|
End-of-day quote
Shenzhen S.E.
2026-04-17
|
5-day change
|
1st Jan Change
|
|
67.19 CNY
|
-0.91%
|
 |
-1.55%
|
-4.41%
|
|
03-12 |
Shenyang Xingqi Pharmaceutical Doses First Patient in Eye Drop Trial
|
MT
| |
03-10 |
Xingqi Pharmaceutical Completes Establishment of New Subsidiary
|
MT
| |
01-05 |
Xingqi Pharmaceutical Gets Nod for Supplementary Application for Atropine Sulfate Eye Drops
|
MT
| |
12-08 |
Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue
|
MT
| |
25-10-28 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
|
CI
| |
25-10-09 |
Shenyang Xingqi Pharmaceutical Gets China Clinical Trial Nod for Macular Edema Injection
|
MT
| |
25-09-16 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 24 September 2025
|
CI
| |
25-08-28 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Cash Dividend for the Year 2025
|
CI
| |
25-08-27 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
|
CI
| |
25-06-17 |
Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel
|
MT
| |
25-05-30 |
Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial
|
MT
| |
25-05-26 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding
|
CI
| |
25-05-15 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Final Cash Dividend Plan on A Shares for 2024, Payable on 22 May 2025
|
CI
| |
25-04-28 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
|
CI
| |
25-04-22 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year 2024
|
CI
| |
25-04-20 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
|
CI
| |
24-10-28 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
|
CI
| |
24-09-22 |
Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index
|
CI
| |
24-09-18 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend for the 2024
|
CI
| |
24-08-29 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024
|
CI
| |
24-08-28 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
|
CI
| |
24-07-25 |
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%
|
MT
| |
24-07-24 |
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%
|
MT
| |
24-05-21 |
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors
|
CI
| |
24-05-15 |
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
